Recent Press Releases

Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy

Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine...

Melanoma Treatment Market Value to More than Quadruple to $5.64 Billion by 2023, says GlobalData

LONDON, UK (GlobalData), 15 April 2015 - The global treatment market for melanoma will expand more than fourfold in value from $1.34 billion in 2013 to reach an estimated $5.64 billion by 2023,...

Data in The Lancet show Novartis drug Arzerra(R) plus chlorambucil improved median progression-free survival by 71% in CLL patients

Significant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic leukemia (CLL)...

Abbott and Sekisui Collaborate to Offer Coagulation Testing for Laboratories Worldwide

- Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots

ABBOTT PARK, Ill.,

FDA ADVISORY COMMITTEE REVIEWS SAVOR OUTCOMES STUDY RESULTS FOR ONGLYZA(R) (SAXAGLIPTIN) AND KOMBIGLYZE(R) XR (SAXAGLIPTIN AND METFORMIN HCI EXTENDED-RELEASE)

AstraZeneca today announced that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13 to 1 (1 abstained; 15 total votes) that the results...

Global Duchenne Muscular Dystrophy Treatment Market to See Spectacular Growth by 2019, says GlobalData

Global Duchenne Muscular Dystrophy Treatment Market to See Spectacular Growth by 2019, says GlobalData Duchenne Muscular Dystrophy (DMD) treatment market value to expand from approximately $8.2...

Johnson & Johnson Reports 2015 First-Quarter Results:

Sales of $17.4 Billion decreased 4.1% Versus 2014 First Quarter; First-Quarter EPS was $1.53 Adjusted 2015 First-Quarter EPS of $1.56 Decreased 4.3%* NEW BRUNSWICK, N.J., April 14, 2015 /PRNewswire/...

Boston Athletic Association And Abbott Announce Multiple-Year Sponsorship Of The Boston Marathon

Sponsorship complements Abbott's title sponsorship of the Abbott World Marathon Majors

BOSTON, April 13, 20

Mylan Settles Patent Litigation Related to Viagra(R)

POTTERS BAR, England, April 13, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals Inc. ("Mylan") have entered into a...

Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians

New analysis will confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show...

Teva to Present Multiple Sclerosis Data at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.

GALA open-label extension study results expound upon effects of COPAXONE® 40 mg/mL Study design detailed for ARPEGGIO, Phase II evaluation of laquinimod in primary-progressive multiple sclerosis...

Novo Nordisk opens new insulin formulation and filling facility in Russia

Moscow, Russia, 10 April 2015 - Today, Novo Nordisk opens a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes. The production will cover...

Eisai Realigns U.S. Operations

WOODCLIFF LAKE, N.J., April 9, 2015 /PRNewswire/ -- Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announced plans to realign its operations in the United States. As part of this...

Qualcomm Announces the Launch of HealthyCircles Mobile

- Adaptive and personalized mobile care experience guides and empowers healthy behaviors -

SAN DIEGO, April

Mylan Proposes To Acquire Perrigo For $205 Per Share

THIS ANNOUNCEMENT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.5 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES 2013 AND THERE CAN BE NO CERTAINTY THAT AN OFFER...